E3 Ligases and Deubiquitinases in GPCR Down Regulation

GPCR 下调中的 E3 连接酶和去泛素酶

• 批准号: 7987494
• 负责人: SUDHA K SHENOY
• 金额: $ 35.33万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7987494
• 关键词: Adaptor Signaling Protein; Address; Adenylate Cyclase; Adrenergic Agents; Adrenergic Receptor; Adrenergic beta-Antagonists; Affect; Affinity; Agonist; Arrestins; Attenuated; Binding; Biological Models; Blood Pressure; Blood Vessels; Cardiac; Cardiac Myocytes; Cardiovascular Physiology; Cardiovascular system; Catecholamines; Cell Line; Cell Surface Receptors; Cell membrane; Cell model; Cell surface; Chronic; Coupled; Coupling; Cyclic AMP; Deubiquitination; Development; Disease; Drug Prescriptions; Epinephrine; Equilibrium; Exercise; Family; Funding; G Protein-Coupled Receptor Signaling; G protein coupled receptor kinase; G-Protein-Coupled Receptors; Goals; Half-Life; Heart; Heart failure; Homeostasis; Knockout Mice; Knowledge; Left Ventricular Function; Ligase; Link; Lysosomes; Maintenance; Mediating; Molecular; Mus; Muscle Cells; Myocardium; Neonatal; Norepinephrine; Pathway interactions; Patients; Phosphorylation; Physiological; Plasma; Play; Post-Translational Protein Processing; Process; Production; Proteins; RNA Interference; Receptor Down-Regulation; Recycling; Regulation; Relaxation; Role; Signal Transduction; Smooth Muscle Myocytes; Staging; Stress; Testing; Ubiquitination; Ventricular; Work; adrenergic; carvedilol; functional loss; improved; in vivo; novel; novel therapeutics; prevent; public health relevance; receptor; receptor internalization; receptor recycling; response; trafficking; ubiquitin ligase; ubiquitin-protein ligase

DESCRIPTION (provided by applicant): G protein coupled receptors (GPCRs) constitute the largest cell-surface receptor family and at least 35% of currently prescribed drugs act on these receptor molecules. GPCR signaling is critically involved in many aspects of cardiovascular function. The magnitude and extent of GPCR signaling is determined by several governing factors including the lifetime of the receptor molecule itself. During the first period of funding, we have found that ubiquitination of the cell-surface b2 adrenergic receptor (b2AR) determines its degradation in lysosomes, thus providing an 'off switch' for attenuating cellular responses. We have identified specific enzymatic activities involved in regulating the intracellular trafficking of agonist-activated b2ARs. Thus, the RING-domain containing E3 ubiquitin ligase Mdm2 ubiquitinates the receptor associated adaptor protein b-arrestin2 and is involved in early steps of receptor internalization while the HECT- domain containing E3 ligase Nedd4 ubiquitinates the b2AR leading to receptor degradation in the lysosomes. Recruitment of both ligases to the b2AR is agonist-dependent and occurs sequentially. We have also shown that two related deubiquitinases (DUBS), USP20 and USP33 reverse this ubiquitination and prevent receptor degradation while concomitantly promoting receptor recycling to the plasma membrane. The central hypothesis for the proposed work in this competing continuation application is: "b-adrenergic signaling is intimately linked to trafficking pathways and involves dynamic regulation by distinct E3 ligases and deubiquitinases". By using aortic vascular smooth muscle cells and neonatal ventricular myocytes as cellular model systems, RNAi and knockout mice, we will define the impact of ubiquitination/deubiquitination dynamics on bAR responsiveness in the cardiovascular system. The specific aims are: 1) To determine the effects of lysosomal trafficking in regulating bAR signaling, 2) To elucidate the molecular mechanisms that define the recruitment and/or activation of deubiquitinases during bAR resensitization and 3) To elucidate the mechanistic role of Mdm2 in bAR signaling in the heart. The long-term goal of this project is to understand the molecular mechanisms that integrate G protein-coupled receptor trafficking and signaling, which could play a critical role in balancing physiological responsiveness. PUBLIC HEALTH RELEVANCE: b adrenergic receptors (b1 and b2 ARs) are expressed in the heart and are important for the contractility of heart muscles, especially during stress and exercising. b2ARs also regulate the relaxation of smooth muscle cells that line the wall of blood vessels in our body. The proposed work will elucidate how cell surface expression and function of the bARs are maintained and the knowledge gained will help the development of novel therapeutics, which could be beneficial in the treatment of heart failure and blood pressure disorders.

描述（由申请人提供）：G蛋白偶联受体（GPCR）构成最大的细胞表面受体家族，目前至少35%的处方药作用于这些受体分子。GPCR信号传导关键地参与心血管功能的许多方面。GPCR信号传导的幅度和程度由几个控制因素决定，包括受体分子本身的寿命。在第一阶段的资金，我们已经发现，泛素化的细胞表面的b2肾上腺素能受体（b2 AR）决定其在溶酶体中的降解，从而提供了一个“关闭开关”衰减细胞反应。我们已经确定了参与调节激动剂激活的b2 AR的细胞内运输的特定酶活性。因此，含有RING结构域的E3泛素连接酶Mdm 2泛素化受体相关衔接蛋白b-抑制蛋白2，并参与受体内化的早期步骤，而含有HECT结构域的E3连接酶Nedd 4泛素化b2 AR，导致溶酶体中的受体降解。两种连接酶募集到b2 AR是激动剂依赖性的，并且顺序发生。我们还表明，两种相关的去泛素化酶（DUBS），USP 20和USP 33逆转这种泛素化，并防止受体降解，同时促进受体再循环到质膜。在这一竞争性继续申请中，拟议工作的中心假设是：“β-肾上腺素能信号传导与运输途径密切相关，并涉及不同的E3连接酶和去泛素化酶的动态调节”。通过使用主动脉血管平滑肌细胞和新生心室肌细胞作为细胞模型系统，RNAi和基因敲除小鼠，我们将定义泛素化/去泛素化动力学对心血管系统中bAR反应性的影响。具体目标是：1）确定溶酶体运输在调节bAR信号传导中的作用，2）阐明在bAR再敏化期间定义去泛素化酶的募集和/或活化的分子机制，和3）阐明Mdm 2在心脏中的bAR信号传导中的机制作用。该项目的长期目标是了解整合G蛋白偶联受体运输和信号传导的分子机制，这可能在平衡生理反应中发挥关键作用。 公共卫生关系：B肾上腺素能受体（b1和b2 AR）在心脏中表达，对心肌的收缩性很重要，特别是在压力和运动期间。b2 ARs还调节我们体内血管壁的平滑肌细胞的松弛。拟议的工作将阐明bAR的细胞表面表达和功能是如何维持的，所获得的知识将有助于开发新的治疗方法，这可能有助于治疗心力衰竭和血压疾病。